1083 related articles for article (PubMed ID: 25537512)
1. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
2. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
3. Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Jun; 27(5):887-894. PubMed ID: 28498253
[TBL] [Abstract][Full Text] [Related]
4. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
9. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells.
Young MJ; Wu YH; Chiu WT; Weng TY; Huang YF; Chou CY
Carcinogenesis; 2015 Apr; 36(4):498-507. PubMed ID: 25742746
[TBL] [Abstract][Full Text] [Related]
12. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
13. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
14. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
17. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
[TBL] [Abstract][Full Text] [Related]
18. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]